Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC3403 vs Anoro (umeclidinium bromide + vilanterol) in COPD
ChiCTR2600120078Phase 3Completed
- Sponsor
- Shenzhen People's Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of TQC3403 in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: Change in trough FEV1 at week 24. Started Mar 2026; status: completed.
02
Drugs
TQC3403
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2600120078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120078.